Hormone replacement therapy / Risk Cancer Research Results

Hormone replacement therapy — Menopausal hormone therapy (MHT), historically termed hormone replacement therapy (HRT), is the therapeutic administration of estrogen with or without a progestogen to replace declining ovarian sex-steroid activity during peri- or postmenopause. It is a systemic or local hormonal drug modality rather than a single molecular agent; common components include 17β-estradiol, conjugated equine estrogens (CEE), micronized progesterone, and synthetic progestins such as medroxyprogesterone acetate (MPA). Standard abbreviations are HRT, HT, MHT, ET for estrogen therapy, and EPT for estrogen-progestogen therapy. Estrogen alone is generally used after hysterectomy, whereas women with an intact uterus receiving systemic estrogen ordinarily require adequate progestogen-mediated endometrial protection. Cancer effects are strongly formulation-, tissue-, duration-, age-, and timing-dependent: HRT should not be classified globally as either cancer-promoting or cancer-protective.

Primary mechanisms (ranked):

1. Estrogen receptor signaling — estradiol and related estrogens activate ERα and ERβ transcriptional programs; in ER-responsive breast and endometrial tissue this can promote proliferation and survival, although biological effects differ by tissue and hormonal context.
2. Progesterone receptor signaling and endometrial opposition — progesterone or progestins activate PR and oppose estrogen-driven endometrial proliferation, markedly reducing the endometrial hyperplasia/cancer risk produced by unopposed systemic estrogen.
3. Breast epithelial proliferation — combined estrogen-progestogen therapy, particularly the CEE plus MPA regimen studied in WHI, increases breast cancer incidence with sufficiently prolonged exposure; the effect is not equivalent to estrogen-alone therapy.
4. Tissue-selective steroid receptor effects — breast, endometrium, ovary, bone, brain, vasculature, liver, and genitourinary tissues respond differently to estrogen/progestogen exposure, producing divergent benefit-risk profiles.
5. Hepatic first-pass signaling — oral estrogen increases hepatic exposure and alters synthesis of coagulation, lipid, inflammatory, and hormone-binding proteins more strongly than transdermal estradiol; this contributes to route-dependent systemic effects.

Bioavailability / PK relevance: HRT exposure depends strongly on molecule and route. Oral estradiol undergoes substantial intestinal/hepatic first-pass metabolism with relatively high estrone and hepatic protein effects. Transdermal estradiol bypasses first-pass hepatic exposure and generally produces more physiologic estradiol-to-estrone profiles. Vaginal low-dose estrogen is intended primarily for local genitourinary effects and usually produces much lower systemic exposure than systemic HRT. Progestogen pharmacology also matters; micronized progesterone and synthetic progestins are not pharmacologically interchangeable.

In-vitro vs systemic exposure relevance: HRT is concentration-driven through steroid-receptor occupancy, but clinically relevant effects occur at physiological or near-physiological systemic hormone concentrations rather than the high micromolar exposures commonly used in experimental cancer-cell studies. Mechanistic conclusions from high-concentration estradiol or progestin experiments should therefore not automatically be extrapolated to menopausal dosing.

Clinical evidence status: Extensive human evidence including large randomized controlled trials and decades of clinical use. HRT is established for menopausal vasomotor symptoms and genitourinary indications and can prevent bone loss in appropriate patients; it is not an anticancer therapy. Cancer effects differ substantially by regimen. WHI randomized evidence shows increased breast cancer incidence with CEE plus MPA, whereas CEE alone in women with prior hysterectomy was associated with lower breast cancer incidence and mortality during long-term follow-up. Unopposed systemic estrogen increases endometrial cancer risk in women with a uterus, while adequate combined estrogen-progestogen therapy substantially suppresses this risk. Current prescribing therefore requires individualized assessment of formulation, route, age, time since menopause, uterus status, prior hormone-sensitive malignancy, cardiovascular and thromboembolic risk, and treatment indication.

HRT Cancer-Relevant Mechanisms

P: 0–30 min    R: 30 min–3 hr    G: >3 hr

Alzheimer’s disease relevance: Menopausal hormone therapy has substantial mechanistic and clinical relevance to cognition but is not an established treatment or prevention strategy for Alzheimer’s disease. Estrogen receptors are widely expressed in the brain and estrogen can influence synaptic plasticity, glucose metabolism, mitochondrial function, cholinergic signaling, cerebral blood flow, and amyloid-related biology. However, randomized clinical evidence has not demonstrated reliable cognitive or dementia prevention benefit. In WHIMS, initiation of CEE plus MPA in women aged 65 years or older increased probable dementia, and CEE alone did not prevent dementia. Trials beginning therapy closer to menopause, including KEEPS-Cog and ELITE-Cog, generally found neither meaningful cognitive benefit nor major cognitive harm. Timing, formulation, age, and baseline vascular/neurodegenerative status appear important, but HRT should not currently be classified as an Alzheimer’s disease therapy.

HRT Alzheimer’s-Relevant Mechanisms

P: 0–30 min    R: 30 min–3 hr    G: >3 hr